Kyverna Therapeutics (KYTX) Stock Chart & Stock Price History $3.46 +0.15 (+4.53%) As of 04:00 PM Eastern Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Kyverna Therapeutics Stock Price Performance The Kyverna Therapeutics (KYTX) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 74.82%, with a year-to-date return of -7.49%. In the past month, the stock has increased 56.56%, reflecting recent market activity. As of the latest close, Kyverna Therapeutics traded at $3.31 with a market cap of $143.06 million and volume of 620,755 shares. Receive KYTX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Kyverna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+2.06%1 Month Performance+56.56%3 Month Performance+36.76%Year-To-Date Performance-7.49%1 Year Performance-74.82% KYTX Stock Chart for Thursday, June, 12, 2025 KYTX Chart by TradingView Kyverna Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization06/12/2025$3.31$3.46+4.53%$3.58$3.18388,003 shs$149.54 million06/11/2025$3.60$3.31-8.06%$3.82$3.29620,755 shs$143.06 million06/10/2025$3.45$3.60+4.35%$3.82$3.47661,238 shs$155.59 million06/09/2025$3.39$3.45+1.77%$3.48$3.18320,718 shs$149.11 million06/06/2025$2.94$3.39+15.31%$3.42$3.02528,572 shs$146.51 million06/05/2025$2.85$2.94+3.16%$3.16$2.70650,094 shs$127.06 million06/04/2025$2.79$2.85+2.15%$2.89$2.75211,646 shs$123.17 million06/03/2025$2.65$2.79+5.28%$2.82$2.60356,387 shs$120.58 million06/02/2025$2.52$2.65+5.16%$2.77$2.55245,807 shs$114.53 million05/30/2025$2.63$2.52-4.18%$2.64$2.47187,872 shs$108.91 million Get the Latest News and Ratings for KYTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Kyverna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 05/29/2025$2.55$2.63+3.14%$2.68$2.52262,044 shs$113.67 million05/28/2025$2.58$2.55-1.16%$2.73$2.43295,718 shs$110.21 million05/27/2025$2.27$2.58+13.66%$2.82$2.451.06 million shs$111.51 million05/26/2025$2.27$2.27$2.47$2.24524,822 shs$98.11 million05/23/2025$2.47$2.27-8.10%$2.47$2.24524,822 shs$98.11 million05/22/2025$2.21$2.47+11.76%$2.49$2.19549,185 shs$106.75 million05/21/2025$2.39$2.21-7.53%$2.42$2.16510,167 shs$95.51 million05/20/2025$2.07$2.39+15.46%$2.42$2.071.01 million shs$103.29 million05/19/2025$2.32$2.07-10.78%$2.33$2.06341,967 shs$89.46 million05/16/2025$2.18$2.32+6.42%$2.41$2.27647,974 shs$100.27 million05/15/2025$2.15$2.18+1.40%$2.19$2.06377,136 shs$94.22 million05/14/2025$2.32$2.15-7.33%$2.37$2.06301,060 shs$92.92 million05/13/2025$2.21$2.32+4.98%$2.32$2.16351,816 shs$100.27 million05/12/2025$2.11$2.21+4.74%$2.24$2.14221,059 shs$95.51 million Related Companies AMLX Stock Price Chart PRTC Stock Price Chart SEPN Stock Price Chart ORKA Stock Price Chart TRML Stock Price Chart MBX Stock Price Chart SIGA Stock Price Chart ZYBT Stock Price Chart UPXI Stock Price Chart ALT Stock Price Chart Receive KYTX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Kyverna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:KYTX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
